These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 37569485)

  • 1. Actions of a Novel Bacterial Topoisomerase Inhibitor against
    Dauda SE; Collins JA; Byl JAW; Lu Y; Yalowich JC; Mitton-Fry MJ; Osheroff N
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bimodal Actions of a Naphthyridone/Aminopiperidine-Based Antibacterial That Targets Gyrase and Topoisomerase IV.
    Gibson EG; Oviatt AA; Cacho M; Neuman KC; Chan PF; Osheroff N
    Biochemistry; 2019 Nov; 58(44):4447-4455. PubMed ID: 31617352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions between Zoliflodacin and
    Collins JA; Basarab GS; Chibale K; Osheroff N
    ACS Infect Dis; 2024 Aug; 10(8):3071-3082. PubMed ID: 39082980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel bacterial topoisomerase inhibitors: unique targeting activities of amide enzyme-binding motifs for tricyclic analogs.
    Mann CA; Carvajal Moreno JJ; Lu Y; Dellos-Nolan S; Wozniak DJ; Yalowich JC; Mitton-Fry MJ
    Antimicrob Agents Chemother; 2023 Oct; 67(10):e0048223. PubMed ID: 37724886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914.
    Kern G; Palmer T; Ehmann DE; Shapiro AB; Andrews B; Basarab GS; Doig P; Fan J; Gao N; Mills SD; Mueller J; Sriram S; Thresher J; Walkup GK
    J Biol Chem; 2015 Aug; 290(34):20984-20994. PubMed ID: 26149691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanistic and Structural Basis for the Actions of the Antibacterial Gepotidacin against Staphylococcus aureus Gyrase.
    Gibson EG; Bax B; Chan PF; Osheroff N
    ACS Infect Dis; 2019 Apr; 5(4):570-581. PubMed ID: 30757898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Target-Mediated Fluoroquinolone Resistance in
    Collins JA; Oviatt AA; Chan PF; Osheroff N
    ACS Infect Dis; 2024 Apr; 10(4):1351-1360. PubMed ID: 38606464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gyrase and Topoisomerase IV: Recycling Old Targets for New Antibacterials to Combat Fluoroquinolone Resistance.
    Collins JA; Osheroff N
    ACS Infect Dis; 2024 Apr; 10(4):1097-1115. PubMed ID: 38564341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel 3-fluoro-6-methoxyquinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.
    Mitton-Fry MJ; Brickner SJ; Hamel JC; Barham R; Brennan L; Casavant JM; Ding X; Finegan S; Hardink J; Hoang T; Huband MD; Maloney M; Marfat A; McCurdy SP; McLeod D; Subramanyam C; Plotkin M; Reilly U; Schafer J; Stone GG; Uccello DP; Wisialowski T; Yoon K; Zaniewski R; Zook C
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3353-3358. PubMed ID: 28610977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diminishing hERG inhibitory activity of aminopiperidine-naphthyridine linked NBTI antibacterials by structural and physicochemical optimizations.
    Kokot M; Weiss M; Zdovc I; Anderluh M; Hrast M; Minovski N
    Bioorg Chem; 2022 Nov; 128():106087. PubMed ID: 35970069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of Action of Mycobacterium tuberculosis Gyrase Inhibitors: A Novel Class of Gyrase Poisons.
    Gibson EG; Blower TR; Cacho M; Bax B; Berger JM; Osheroff N
    ACS Infect Dis; 2018 Aug; 4(8):1211-1222. PubMed ID: 29746087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vitro and In Vivo Characterization of the Novel Oxabicyclooctane-Linked Bacterial Topoisomerase Inhibitor AM-8722, a Selective, Potent Inhibitor of Bacterial DNA Gyrase.
    Tan CM; Gill CJ; Wu J; Toussaint N; Yin J; Tsuchiya T; Garlisi CG; Kaelin D; Meinke PT; Miesel L; Olsen DB; Lagrutta A; Fukuda H; Kishii R; Takei M; Oohata K; Takeuchi T; Shibue T; Takano H; Nishimura A; Fukuda Y; Singh SB
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4830-9. PubMed ID: 27246784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent DNA gyrase inhibitors bind asymmetrically to their target using symmetrical bifurcated halogen bonds.
    Kolarič A; Germe T; Hrast M; Stevenson CEM; Lawson DM; Burton NP; Vörös J; Maxwell A; Minovski N; Anderluh M
    Nat Commun; 2021 Jan; 12(1):150. PubMed ID: 33420011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of aminopiperidine based potent & novel topoisomerase inhibitor with broad spectrum anti-bacterial activity.
    Desai J; Patel B; Panchal N; Gite A; Darji B; Viswanathan K; Trivedi J; Vyas P; Pawar V; Giri P; S S; Sharma R; Jain M; Iyer P; Kumar S
    Bioorg Med Chem Lett; 2024 Oct; 111():129911. PubMed ID: 39067715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dioxane-Linked Amide Derivatives as Novel Bacterial Topoisomerase Inhibitors against Gram-Positive
    Lu Y; Papa JL; Nolan S; English A; Seffernick JT; Shkolnikov N; Powell J; Lindert S; Wozniak DJ; Yalowich J; Mitton-Fry MJ
    ACS Med Chem Lett; 2020 Dec; 11(12):2446-2454. PubMed ID: 33335666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure activity relationship of N-1 substituted 1,5-naphthyrid-2-one analogs of oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-9).
    Singh SB; Tan CM; Kaelin D; Meinke PT; Miesel L; Olsen DB; Fukuda H; Kishii R; Takei M; Ohata K; Takeuchi T; Shibue T; Takano H; Nishimura A; Fukuda Y
    Bioorg Med Chem Lett; 2022 Nov; 75():128808. PubMed ID: 35609741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacy.
    Dougherty TJ; Nayar A; Newman JV; Hopkins S; Stone GG; Johnstone M; Shapiro AB; Cronin M; Reck F; Ehmann DE
    Antimicrob Agents Chemother; 2014 May; 58(5):2657-64. PubMed ID: 24566174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Structural Features of Novel Bacterial Topoisomerase Inhibitors That Define Their Activity on Topoisomerase IV.
    Kokot M; Anderluh M; Hrast M; Minovski N
    J Med Chem; 2022 May; 65(9):6431-6440. PubMed ID: 35503563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual inhibition of Staphylococcus aureus DNA gyrase and topoisomerase IV activity by phenylalanine-derived (Z)-5-arylmethylidene rhodanines.
    Werner MM; Patel BA; Talele TT; Ashby CR; Li Z; Zauhar RJ
    Bioorg Med Chem; 2015 Sep; 23(18):6125-37. PubMed ID: 26320664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclohexyl amide-based novel bacterial topoisomerase inhibitors with prospective GyrA-binding fragments.
    Kolarič A; Novak D; Weiss M; Hrast M; Zdovc I; Anderluh M; Minovski N
    Future Med Chem; 2019 May; 11(9):935-945. PubMed ID: 31140866
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.